-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Raises Price Target to $40

Benzinga·11/05/2026 11:36:30
HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $22 to $40.